BACARDI
6.3.2017 13:32:42 CET | Business Wire | Press release
Family-owned Bacardi Limited, the world’s largest privately held spirits company, today announced that Mahesh Madhavan, a 20-year Bacardi veteran who is currently a member of the Company’s Global Leadership Team and Regional President of Asia, Middle East & Africa, will succeed Michael J. Dolan, who will retire as Chief Executive Officer, effective April 1, 2018. In the interim, Dolan will continue as CEO, while Madhavan will transition to a new role as Regional President of Europe for much of 2017. Dolan will continue to serve on the Bacardi Limited Board of Directors until the 2019 Annual General Meeting, when he will retire from the company.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170306005376/en/
Facundo L. Bacardi, Chairman of the Board of Bacardi Limited, said, “On behalf of the Board, we are delighted to name Mahesh as the next CEO of Bacardi Limited. For almost three years, the Board has conducted a rigorous succession planning process to ensure an orderly transition of leadership. With a proud history that dates back 155 years, it is critical to us to advance our goals as a company in a manner consistent with our culture. As a long-time Bacardi executive, Mahesh has the ideal mix of leadership skills, commercial, operational and financial expertise, and global brands experience. Importantly, he fully embraces our culture, history, and values, and he is an exemplary leader of people. We have great confidence in Mahesh and his vision to lead Bacardi well into the future, providing continuity of leadership to build on our success during Mike’s tenure and capitalize on the momentum of our brands and the tremendous global opportunity in both developed and emerging markets.”
Dolan has worked with Bacardi since 2009, when he joined the Board of Directors, and has demonstrated a deep understanding of both the business and unique values of Bacardi. During Dolan’s leadership as CEO since 2014, the Company has taken a disciplined approach to increase operational efficiencies, reduce costs, and re-invest in its iconic portfolio of brands.
“Our team is proud of the work we’ve done to strengthen the financial position of the company and improve the topline through a sharp focus on enhancing the equity of our core brands. We’re delivering cost savings and reinvesting those savings in incremental advertising and promotion activities designed to captivate a new generation of consumers,” said Dolan. “As importantly, we have stabilized our leadership team and created robust development programs to build a deep bench of global talent. I have no doubt that with his long tenure, tremendous leadership qualities, and global perspective, Mahesh will continue to drive growth and brand momentum while nurturing our culture and our people. I look forward to partnering with him as he prepares to assume his new responsibilities.”
Said Madhavan, “It is an extraordinary honor to be selected as the next CEO of Bacardi Limited. I know I speak for so many of my colleagues when I say that it is a privilege to work for a family-owned company with such a storied history that has thrived through many generations. Our strong culture is built on the spirit of entrepreneurship and working together as one team, with a focus on equity and fairness. I will execute the stewardship of this Company with the great care it deserves, and am fortunate to assume this important role with the support of Facundo and Mike, and with the benefit of a talented management team whose solid execution has positioned the Company well for significant long-term growth. We have many exciting opportunities ahead of us, and we are in the ideal position to capitalize on global spirits trends with iconic brands in the premium and ultra-premium segments.”
Madhavan currently leads the Company’s Asia, Middle East & Africa operations, where he has been charged with building stronger connections between the iconic brands in the Bacardi portfolio and consumers in those fast-growing regions. During his tenure, he has held leading roles within various emerging markets including Managing Director of India, Managing Director for Thailand and the Philippines, and Managing Director of South Asia and Southeast Asia. He has also led the Company’s Emerging Market Council. Madhavan will immediately assume the role of Regional President of Europe, BMBV, and will be based in Geneva until he assumes the CEO role, at which time he is expected to move to the Company’s global headquarters in Bermuda, subject to immigration approvals.
The Company also announced that, as part of the leadership succession plan, Paolo Perego, currently Regional President of Europe, BMBV, will depart to pursue other opportunities and the Company thanks him for his considerable contributions. Alex Ouziel, a seven-year veteran of Bacardi and currently VP & Managing Director of Eastern Europe, has been promoted to Regional President of Asia, Middle East & Africa, based in Dubai, succeeding Madhavan. Ouziel will also join the Global Leadership Team. Oksana Pevtsova, a 10-year veteran of the Company, has been promoted to VP & Managing Director of Eastern Europe, based in Moscow, replacing Ouziel.
Bacardi added, “It’s a pleasure to announce the promotions of Alex and Oksana. Their success demonstrates the commitment our Company has made to identifying and nurturing internal talent.”
The leadership succession process was led by a Special Committee of the Board, advised by Dr. John A. Davis and Dr. David Ager of Cambridge Family Enterprise Group, leading experts on family businesses.
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands.
Founded 155 years ago in Santiago de Cuba on February 4, 1862, family-owned Bacardi manufactures its brands at 29 facilities and sells in more than 160 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. www.BacardiLimited.com
©2017 BACARDI
BACARDI, THE BAT DEVICE AND OTHER MARKS ARE
TRADEMARKS OF BACARDI & COMPANY LIMITED
OR OF OTHER
SUBSIDIARIES OF BACARDI LIMITED
View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005376/en/
Contact:
Bacardi Limited
Amy Federman, +1-441-294-1110
afederman@bacardi.com
or
K.C.
Kavanagh, +1-441-298-1053
kckavanagh@bacardi.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
